Table 1.
a | Patient demographics (total cohort, n=528) | |
---|---|
Characteristics | |
Age (years), mean±s.d. | 60 ± 17 |
Female % (n) | 39.8 (210) |
Weight (kg), mean±s.d. | 80 ± 19 |
APACHE II score, mean±s.d. | 18 ± 6.4 |
SOFA score, mean±s.d. | 6.3 ±2.8 |
Primary diagnosis (%) (n) | |
Abdominal aortic aneurysm rupture and repair | 4.5 (24) |
Abdominal surgery or inflammation | 10.2 (54) |
Burns | 0.9 (5) |
Cardiac arrest or failure | 11.9 (63) |
Cardiac surgery | 17.8 (94) |
Collapse, cause unknown | 0.6 (3) |
Neurological surgery, injury, or seizure or hemorrhage | 14.0 (74) |
Other | 0.6 (3) |
Pulmonary or thoracic surgery or failure | 12.1 (64) |
Sepsis | 19.1 (101) |
Trauma | 8.1 (43) |
Outcomes (%) (n) | |
AKIN on entry | 27.8 (147) |
AKIN48 | 15.5 (82) |
RIFLE24 | 5.1 (27) |
Dialysis within 7 days | 3.6 (19) |
Died within 7 days | 10.2 (54) |
b | Urinary biomarker concentrations on entry | |||||
---|---|---|---|---|---|
N | Mean±s.d. | Median (IQR) | Min | Max | |
GGT (Units/l)/mmol/l Cr | 526 | 28 ±55 | 13 (7–25) | 1.9 | 923 |
AP (Units/l)/mmol/l Cr | 526 | 1.7 ± 4.1 | 0.89 (0.46–1.8) | 0.00025 | 74.8 |
CysC (mg/l)/mmol/l Cr | 522 | 0.40 ± 1.1 | 0.016 (0.001–0.17) | 0.0001 | 9.3 |
NGAL (ng/ml)/mmol/l Cr | 487 | 140 ±410 | 8.0 (2.5–41) | 0.0001 | 3000 |
IL-18 (pg/ml)/mmol/l Cr | 523 | 73 ± 340 | 0.001 (0.001–36)a | 0.0001 | 3100 |
KIM-1 (pg/ml)/mmol/l Cr | 524 | 300 ± 1400 | 86 (37–210) | 0.56 | 2800 |
Abbreviations: AKI, acute kidney injury; AKIN48, AKI within 48 h; APACHE II, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit; SOFA, Sequential Organ Failure Assessment.
Table modified from the study by Endre et al., 2010.16
AKIN on entry: ≥0.3 mg/dl or ≥50% increase in plasma creatinine from baseline on entry to the ICU.
AKIN48: Not AKIN on entry and ≥0.3 mg/dl or ≥50% increase in plasma creatinine from baseline within ~48 h.
RIFLE24: Not AKIN on entry and X50% increase in plasma creatinine sustained for ≥24h within 7 days.
Abbreviations: AP, alkaline phosphatase; Cr, creatinine; CysC, cystatin C; GGT, γ-glutamyltranspeptidase; IL-18, interleukin-18; IQR, interquartile range; KIM-1, kidney injury molecule-1; NGAL, neutrophil-gelatinase-associated lipocalin.
See distribution in Figure 1.